Home › Trials › NCT06835218

Registry for prostate cancer treatment and outcomes

PROstate CAncer Real World Evidence Registry: RECURRENT AND METASTATIC PROSTATE CANCER

Observational UroTrials Company (GmbH) · NCT06835218

This study is tracking the treatment and progress of men with recurrent and advanced prostate cancer to see how different therapies affect their lives over time.

Quick facts

Study typeObservational
Enrollment5000 (estimated)
Ages18 Years and up
SexMale
SponsorUroTrials Company (GmbH) Research network
Drugs / interventionsradiation
Locations53 sites (Freiburg im Breisgau, Baden-Wurttemberg and 52 other locations)
Trial IDNCT06835218 on ClinicalTrials.gov

What this trial studies

This observational registry aims to document the treatment course and disease progression in patients with recurrent and metastatic prostate cancer. It includes various cohorts such as those with biochemical recurrence after local treatment, non-metastatic castration-resistant prostate cancer, and metastatic hormone-sensitive and castration-resistant prostate cancer. Patients will be followed over time with routine data collection on their treatment and quality of life, allowing for a comprehensive understanding of real-world outcomes. The study does not specify any particular treatment, as all therapies will be determined by the treating physicians.

Who should consider this trial

Good fit: Ideal candidates include adult patients diagnosed with different stages of prostate cancer, particularly those experiencing biochemical recurrence or metastatic disease.

Not a fit: Patients with early-stage prostate cancer who have not yet undergone treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this registry could provide valuable insights into the effectiveness of various treatments for prostate cancer, ultimately improving patient care.

How similar studies have performed: Other observational studies have successfully documented treatment outcomes in prostate cancer, suggesting that this approach is both valid and valuable.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adult prostate cancer patients (age ≥18 years).
* Diagnosis at time of study inclusion Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof) Cohort 2: non-metastatic castration-resistant prostate cancer (nmCRPC) or Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line)
* Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC or non-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, … line).
* For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient.
* Patients, who are able and willing to sign the informed consent form

Exclusion Criteria:

• Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician

Where this trial is running

Freiburg im Breisgau, Baden-Wurttemberg and 52 other locations

+3 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Prostate CancerBiochemical Recurrence of Malignant Neoplasm of ProstateNon-metastatic Castration-resistant Prostate CancerMetastatic Hormone-sensitive Prostate CancerMetastatic Castration-resistant Prostate Cancerprostate, cancer, metastatic, systemic therapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.